FindTrial
Sign In

AZD8055

DRUG5 trials

Sponsors

AstraZeneca, National Cancer Institute (NCI)

Conditions

Advanced Hepatocellular CarcinomaAdvanced Solid MalignanciesAdvanced Solid TumoursAnaplastic AstrocytomaAnaplastic OligodendrogliomaBrainstem GliomaCancerGlioblastoma Multiforme

Phase 1

A Study of Tor Kinase Inhibitor in Advanced Tumors
CompletedNCT00731263
AstraZenecaSolid Tumors
Start: 2008-07-31End: 2010-11-30Updated: 2012-07-11
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
CompletedNCT00973076
AstraZenecaAdvanced Solid Malignancies, Cancer, Solid Tumors
Start: 2009-08-31End: 2010-12-31Updated: 2011-06-15
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
CompletedNCT00999882
AstraZenecaAdvanced Hepatocellular Carcinoma, Cancer
Start: 2009-10-31End: 2011-12-31Updated: 2012-07-10
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
WithdrawnNCT01194193
AstraZenecaAdvanced Solid Tumours, Cancer, Lymphomas
Target: 63Updated: 2011-05-16
AZD8055 for Adults With Recurrent Gliomas
CompletedNCT01316809
National Cancer Institute (NCI)Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Brainstem Glioma +2
Start: 2011-03-04End: 2016-04-04Updated: 2019-12-12